Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy

Quality of Life Research

Volumn 8, Issue 8, 1999, Pages 723-731

  Fairclough, Diane L ^a   Fetting, John H ^b   Cella, David ^c   Wonson, Wendy ^d   Moinpour, Carol M ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^d ECOG Coordinating Center   (United States)

^e SW Oncol Group Statistical Center   (United States)

Author keywords

Adjuvant chemotherapy; Breast neoplasms; Quality of life; Randomized clinical trial

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HORMONE RECEPTOR; VINCRISTINE;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 0033510731     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008806828316     Document Type: Article

References (15)

1. 1. Fetting J, Gray R, Abeloff M, Fowble B, Smith T, Vail S, Durrani G, Eudey L, Henney J, Morgolin K, Citron M, Osborne D, Henderson C. CAF vs. a 16-week multidrug regimen as adjuvant therapy for receptor-negative, node positive breast cancer: An Intergroup study. Proc Am Soc Clin Oncol 1995; 114: 96 (#83).
2. 2. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. J Clin Oncol 1989; 7: 36-44.
3. 3. Gelber RD, Goldhirsch A, Cavalli F. Quality of Life Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer. Annals of Internal Med 1991; 114: 621-628.
4. 4. Gelber RD, Cole BF, Gelber S, Goldhirsch A. Comparing treatments using quality-adjusted survival: the Q-TWiST method. The Am Stat 1995; 49: 161-169.
5. 5. Moinpour C, Feigl P, Metch B, et al. Quality of Life endpoints in cancer clinical trails: Review and recommendations. JNCI 1989; 81: 485-495.
6. 6. Levine M, Guyatt G, Gent M, DePauw S, Goodyear MD, Hryniuk WM, Arnold A, Findlay B, Skillings JR, Bramwell VH, Levin L, Bush H, Abu-Zahra H, Kotalik J. Quality of life in stage II breast cancer: An instrument for clinical trials. J Clin Oncol 1988; 6: 1798-1810.
7. 7. Fetting JH, Gray R, Fairclough DL, Smith TJ, Margolin KA, Citron ML, Grove-Conrad M, Cella DL, Pandya K, Robert N, Henderson IC, Osborne CK, Abeloff MD. A 16-week Multidrug Regimen vs. cyclophosphamide, doxorubicin, and 5-Flurouracil (CAF) as Adjuvant Therapy for Node-Positive, Receptor Negative Breast Cancer: An Intergroup Study. J Clin Oncol, 1998; 16: 2382-2391.
8. 8. Hollander M, Wolfe DA. Nonparametric Statistical Methods. NY: John Wiley and Sons, 1973: 50-52, 75-82.
9. 9. Fairclough DF. Quality of Life in Cancer Clinical Trials: Now that we have the data, what do we do? J Appl Stat Sci 1996; 4: 253-269.
10. 10. Weeks J. Personal communication, 1996.
11. 11. O'Leary JF, Fairclough DL, Jankowski MK, Weeks JC. Comparison of Time-tradeoff Utilities and Rating Scale Values of Cancer Patients and their Relatives. Med Decis Making 1995; 15: 132-137.
12. 12. Fetting J. Personal communication, 1997.
13. 13. Hurny C, Bernhard J, Coates AS, Castigilione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 1996; 347: 1279-1284.
14. 14. Fairclough DL, Fetting J, Cella D, et al. Quality of Life on A Breast Cancer Adjuvant Trial Comparing CAF with a 16-week Regimen. Proc Am Soc Clin Oncol 1995; 114: (#890).
15. 15. Smith TJ, Hilner BE. The efficient and cost-effectiveness of Adjuvant Therapy of Early Bresist Cancer in Premenopausal Women. J Clin Oncol 1993; 11: 771-776.